Sydney Lupkin
Sydney Lupkin is the pharmaceuticals correspondent for NPR.
She was most recently a correspondent at Kaiser Health News, where she covered drug prices and specialized in data reporting for its enterprise team. She's reported on how tainted drugs can reach consumers, how companies take advantage of rare disease drug rules and how FDA-approved generics often don't make it to market. She's also tracked pharmaceutical dollars to patient advocacy groups and members of Congress. Her work has won the National Press Club's Joan M. Friedenberg Online Journalism Award, the National Institute for Health Care Management's Digital Media Award and a health reporting award from the Society for Advancing Business Editing and Writing.
Lupkin graduated from Boston University. She's also worked for ABC News, VICE News, MedPage Today and The Bay Citizen. Her internship and part-time work includes stints at ProPublica, The Boston Globe, The Boston Herald, The New England Center for Investigative Reporting and WCVB.
-
The Food and Drug Administration is working on a playbook for how it could greenlight vaccine tweaks. Studies in hundreds of people, rather than tens of thousands, seem likely. -
Coronavirus variants are on the rise, which means changes to the COVID-19 vaccines will be needed. How will the companies do that efficiently, and what will the Food and Drug Administration require?
-
The two companies producing COVID-19 vaccines for use in the United States will have to raise production to meet contractual goals of 100 million doses each by the end of March.
-
Moderna is rapidly increasing production of COVID-19 vaccine for the U.S., and Pfizer is lagging behind. NPR looks at the production trends to see what it means for vaccination drives.
-
The two companies making COVID-19 vaccines each promised to deliver 100 million doses to the federal government by the end of March. So far, they appear to be running behind.
-
The COVID-19 vaccine rollout faces another bottleneck: Pfizer and Moderna may be unable to fulfill contractual promises to deliver 100 million doses a piece to the federal government by March 31.
-
A federal manufacturing contract to increase COVID-19 vaccine production has an unusual clause that could move a company's employees and their families to the front of the vaccination line.
-
Emergent BioSolutions is under contract with Operation Warp Speed to make COVID-19 vaccines, but the terms could allow employees and their families to get vaccinated ahead of schedule.
-
The federal government reaches an agreement with Pfizer to buy an additional 100 million doses of the COVID-19 vaccine. NPR explores what that means for the country's supply in the coming months.
-
The drugmakers will add an additional 100 million COVID-19 vaccine doses to the number that they are already supplying the government. They expect to deliver all the doses by July 31.
